The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Heat shock proteins in cancer: chaperones of tumorigenesis
Calderwood, S. K., Khaleque, M. A., Sawyer, D. B., & Ciocca, D. R. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.01.006 · Cited by 957
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Batist, G., Tulpule, A., Sinha, B. K., Katki, A. G., Myers, C. E., & Cowan, K. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66748-1 · Cited by 789
(1990) · PubMed · Cited by 757
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Super pH-Sensitive Multifunctional Polymeric Micelle
Lee, E. S., Na, K., & Bae, Y. H. (2005) · Nano Letters · doi:10.1021/nl0479987 · Cited by 611
The role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 548
Characterization of nanoparticle uptake by endothelial cells
Davda, J., & Labhasetwar, V. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00923-1 · Cited by 524
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340
Panyam, J., Sahoo, S. K., Prabha, S., Bargar, T., & Labhasetwar, V. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00295-3 · Cited by 308
Self-citationOyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296
Targeting cancer cells with biotin–dendrimer conjugates
Yang, W., Cheng, Y., Xu, T., Wang, X., & Wen, L.-P. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.04.021 · Cited by 290
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery
Patil, Y. B., Toti, U. S., Khdair, A., Ma, L., & Panyam, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.056 · Cited by 242
Self-citationQaddoumi, M. G., Ueda, H., Yang, J., Davda, J., Labhasetwar, V., & Lee, V. H. L. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000022411.47059.76 · Cited by 229
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma
Turk, M. J., Waters, D. J., & Low, P. S. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.12.028 · Cited by 196
Panyam, J., & Labhasetwar, V. (2004) · Molecular Pharmaceutics · doi:10.1021/mp034002c · Cited by 195
Self-citationThe Mechanism of Action of Multidrug-Resistance-Linked P-Glycoprotein
Sauna, Z. E., Smith, M. M., Müller, M., Kerr, K. M., & Ambudkar, S. V. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012875105006 · Cited by 178
Linnet, K., & Ejsing, T. B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.003 · Cited by 163
Kaul, G., & Amiji, M. M. (2004) · Journal of drug targeting · doi:10.1080/10611860400013451 · Cited by 159
Liscovitch, M., & Ravid, D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.01.013 · Cited by 152
Interstitial Stress and Fluid Pressure Within a Growing Tumor
Sarntinoranont, M., Rooney, F. J., & Mauro Ferrari, B. (2003) · Annals of Biomedical Engineering · doi:10.1114/1.1554923 · Cited by 150
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Pulkkinen, M., Pikkarainen, J. T., Wirth, T., TARVAINEN, T., Haapa‐aho, V., KORHONEN, H., Seppälä, J. V., & Järvinen, K. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.04.018 · Cited by 124
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
Chavanpatil, M. D., Patil, Y. B., & Panyam, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.045 · Cited by 124
Self-citationThe pharmacology of cancer resistance.
O'Connor, R. A. (2007) · PubMed · Cited by 123
Surfactant–Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux
Chavanpatil, M. D., Khdair, A., Gérard, B., Bachmeier, C. J., Miller, D. W., Shekhar, M. P. V., & Panyam, J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070024d · Cited by 117
Self-citationAltenberg, G. A., Vanoye, C. G., Horton, J. K., & Reuss, L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4654 · Cited by 113
Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers
Zhao, J. F., Liu, C., Yuan, Y., Tao, X., Shan, X.-Q., Sheng, Y., & Wu, F. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.10.012 · Cited by 104
Watanabe, T., Tsuge, H., Oh‐hara, T., Naito, M., & Tsuruo, T. (1995) · Acta Oncologica · doi:10.3109/02841869509093961 · Cited by 103
Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons
Townsend, S. A., Evrony, G. D., Gu, F., Schulz, M. P., Brown, R. H., & Langer, R. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.011 · Cited by 101
Hubensack, M., Müller, C., Höcherl, P., Fellner, S., Spruß, T., Bernhardt, G., & Buschauer, A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0323-9 · Cited by 97
UEA I-bearing nanoparticles for brain delivery following intranasal administration
Gao, X., Chen, J., Tao, W.-Q., ZHU, J., Zhang, Q., CHEN, H., & JIANG, X. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.039 · Cited by 96
Salem, A. K., Cannizzaro, S. M., Davies, M. C., Tendler, S. J. B., Roberts, C. J., Williams, P. M., & Shakesheff, K. M. (2001) · Biomacromolecules · doi:10.1021/bm010030+ · Cited by 84
Morschhauser, F., Zinzani, P. L., Burgess, M., Sloots, L., Bouafia, F., & Dumontet, C. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701190169 · Cited by 81
MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Lage, H. (2006) · Current Drug Targets · doi:10.2174/138945006777709566 · Cited by 78
Bentham Science Publisher Stein, W. D., Bates, B. S. P., & Bentham Science Publisher Fojo, T. (2004) · Current Drug Targets · doi:10.2174/1389450043345489 · Cited by 59
Lee, G. Y., Park, K., Nam, J. H., Kim, S.-Y., & Byun, Y. (2006) · Journal of drug targeting · doi:10.1080/10611860600935701 · Cited by 55
Molecular and pharmacological strategies to overcome multidrug resistance
Shabbits, J. A., Krishna, R., & Mayer, L. D. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.4.585 · Cited by 51
What does Multidrug Resistance (MDR) Expression Mean in the Clinic?
Duhem, C., Ries, F., & Dicato, M. A. (1996) · The Oncologist · doi:10.1634/theoncologist.1-3-151 · Cited by 46
Debotton, N., Parnes, M., Kadouche, J., & Benita, S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.014 · Cited by 35
Chang, C.-C., Liang, Y., Klutz, A. M., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0214-9 · Cited by 30
Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics
Bebawy, M., & Sze, D. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497168 · Cited by 20
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review
Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.049 · Cited by 1,286
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Metadata
- Authors
- Patil, Y., Sadhukha, T., Ma, L., & Panyam, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2009-05-21
- Volume
- 136
- Issue
- 1
- Pages
- 21-29
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2064674946
- Cited by
- 317
- References
- 54
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.